Atara Biotherapeutics, Inc.
ATRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $94,161 | $63,938 | $142,284 |
| - Cash | $5,742 | $16,903 | $13,841 | $25,030 |
| + Debt | $46,981 | $15,426 | $80,496 | $43,831 |
| Enterprise Value | – | $92,684 | $130,593 | $161,085 |
| Revenue | $3,453 | $17,575 | $98,149 | $32,753 |
| % Growth | -80.4% | -82.1% | 199.7% | – |
| Gross Profit | $3,338 | $17,021 | $77,710 | $25,958 |
| % Margin | 96.7% | 96.8% | 79.2% | 79.3% |
| EBITDA | -$3,330 | $3,598 | $40,822 | -$10,595 |
| % Margin | -96.4% | 20.5% | 41.6% | -32.3% |
| Net Income | -$4,303 | $2,387 | $38,010 | -$12,693 |
| % Margin | -124.6% | 13.6% | 38.7% | -38.8% |
| EPS Diluted | -0.32 | 0.19 | 3.5 | -1.19 |
| % Growth | -268.4% | -94.6% | 394.1% | – |
| Operating Cash Flow | -$9,787 | -$7,318 | -$28,138 | -$24,471 |
| Capital Expenditures | $0 | $0 | $0 | -$90 |
| Free Cash Flow | -$9,787 | -$7,318 | -$28,138 | -$24,561 |